With us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive and tells us which developments he’ll be watching closely in 2020.
For stakeholders in the US biosimilars market, the past few months have been exciting times. We’ve seen multiple product approvals, and the launch of a number of highly anticipated and long-awaited biosimilar products. With us on the podcast today to talk about these developments is Sean McGowan, senior director of biosimilars at AmerisourceBergen.
McGowan is responsible for leading strategy and business development initiatives for the biosimilar product category, and partners with biosimilar manufacturers in the precommercial, launch, and postlaunch phases. He also leads internal collaboration with customer groups to guarantee open access to biosimilars. McGowen spoke with us about the recent biosimilar launches in the United States, what the US biosimilars market needs now in order to thrive, and developments ahead in 2020.
Read more about the upcoming launches of multiple biosimilars from Pfizer, about Truxima, about Ziextenzo, and about Ogivri.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.